Amir Kaki, MD, the principal investigator for the Impella ECP Pivotal Study, discusses data he presented to a large crowd at TCT 2024. Dr. Kaki explains that the 9 Fr Impella ECP, which expands to 21 Fr when deployed, increases access to robust hemodynamic support among patients in whom such support was previously prohibitive. He highlights his experiences of how Impella ECP enabled safe PCI in high-risk patients. He also explains that operators were able to choose whichever vascular closure device they were most comfortable with in the trial and that many operators chose Angio-Seal®. “And what we found, is in the patients who got Angio-Seal as a single vascular closure device, 92% of them were successfully closed, which I think is very remarkable.”